Skip to main content
. 2017 Feb 1;8(12):19712–19722. doi: 10.18632/oncotarget.14966
DNMT1 F:AACCTTCACCTAGCCCCAG R:CTCATCCGATTTGGCTCTTTCA
DNMT3A F:GACAAGAATGCCACCAAAGC R:CCATCTCCGAACCACATGAC
DNMT3B F:AGGGAAGACTCGATCCTCGTC R:CGTCTCCGAACCACATGAC
DNMT3B1 F:AGAATCAAGGAAATACGAGAACAA R:ATCTTCATCCCCTCGGTCTTT
DNMT3B3 F:CCGGGATGAACAGGATCTTT R:AGTAGTCCTTCAGAGGGGCG
DNMT3B4 F:CGGTTCCTGGAGTGTAATCC R:GGTTATTGTCTGTACTTTCTTTAACTGTT
DNMT3B5 F:AATACAATAGGATAGCCAAGGATCT R:TTCAGAGGGGCGAAGAGG
DNMT3B6 F:CCAAGCTTGGAAAGCATGAA R:CCGTTGACGAGGATCGAGT
DNMT3B7 F:CAGTCTAATTACCTTTCACAGAGAACA R: GTCTTGAGGCGCTTGGGT
RASSF1A F:AGGACGGTTCTTACACAGGCT R:TGGGCAGGTAAAAGGAAGTGC
Beta-actin F:CATGTACGTTGCTATCCAGGC R: CTCCTTAATGTCACGCACGAT